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ABSTRACT
Blastocystis sp. is an enteric protist commonly found in human fecal samples. In Brazil, 
few studies have been developed, but none of them has explored the presence of Blastocystis 
in patients with diabetes mellitus. We evaluated the occurrence and molecular identification of 
Blastocystis sp. among patients with diabetes mellitus in the Midwest region, Goias State, Brazil. 
Genomic DNA was obtained from 175 fecal samples (99 from the diabetic group and 76 from the 
control group). PCR was performed using pan-Blastocystis primers from the SSU-rDNA gene. 
Microscopic examination revealed positivity of 12.1% and 7.9% for Blastocystis in diabetics 
and in controls, respectively. Amplification of Blastocystis DNA was observed in 34.4% (34 
of 99) and 30.3% (23 of 76) from the diabetic and control groups, respectively. Phylogenetic 
analyses and BLAST searches revealed six subtypes among Blastocystis isolates in the diabetic 
group, represented by ST1 (38.2%), ST2 (11.8%), ST3 (35.3%), ST6 (2.9%), ST7 (2.9%) and 
ST8 (8.8%). In the control group, ST1 (21.8%), ST2 (21.8%), ST3 (43.5%), ST6 (4.4%) and 
ST8 (8.7%) were identified. This study is the first report regarding the occurrence and subtypes 
distribution of Blastocystis in patients with diabetes mellitus in Brazil. The results reinforce 
the potential risk of Blastocystis infection in patients with diabetes, in addition, it contributes 
to the understanding of the genetic diversity of this enigmatic organism.
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INTRODUCTION
Diabetes is a metabolic disease that has become more frequent over the 
years, and has a worldwide distribution1. Type 2 diabetes (T2D) is responsible 
for approximately 90% of the cases of diabetes mellitus2. This disease has been 
considered a serious health problem in Brazil and worldwide, both in terms of the 
number of affected people, as well as disabilities and premature deaths2-4.
Intestinal parasites continue to be considered an important public health problem 
worldwide, responsible for high morbidity and mortality, especially in developing 
countries1,5. Blastocystis sp. has been highly reported in routine parasitological 
examinations, being one of the most prevalent enteric protists in human fecal 
samples6. On the other hand, its ability to cause disease is debated, and it is a 
subject of ongoing research7. Molecular studies have demonstrated a variable 
genetic diversity with description of 17 distinct subtypes (STs) to date, 10 of which 
have been found in humans (ST1-9 and ST12)7,8. In addition, it has been shown 
that certain subtypes can be considered more pathogenic to humans than others6,7.
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Intestinal parasites and diabetes have been constantly 
evaluated, mainly due to the possibility of immune 
dysfunction in diabetes allowing the development of more 
severe parasitic infections9. In this context, certain parasitic 
infections can occur more frequently in patients with 
diabetes mellitus than in non-diabetics1,5,10. On the other 
hand, the occurrence of Blastocystis sp. is little known, 
especially in patients with diabetes1,5. Studies carried out 
in the Midwest region of Brazil indicate positivity ranging 
from 0.5 to 40.9% for Blastocystis sp., but none of them 
analyzed patients with diabetes11-14. Here, we present data 
on the occurrence and on the molecular identification of 
Blastocystis sp. in fecal samples of patients with diabetes 
mellitus living in Jatai, Goias State, Brazil. 
MATERIALS AND METHODS
Ethical Statement
The present study was approved by the Ethics and 
Research Committee of Universidade Federal de Goias 
(protocol Nº 929187/2015). After written informed consent 
was obtained, one fecal sample from each participant was 
collected.
Study site
This study was carried out from January 2015 to 
December 2016 in the Jatai municipality, Goias State, 
which is located in the Midwest region of Brazil 
(17º52’33”S, 51º43’17”W), 535 km from Brasilia (the 
capital of Brazil). Jatai has a total population of 100,882 
inhabitants15.
Sampling
This study included unpreserved fecal samples from 
individuals of both genders, with ages ranging from 18 to 
89 years old. The individuals were divided into two groups:
- The diabetic group (n = 99) was composed of patients 
with type 2 diabetes mellitus (T2D) attending the 
Program of Education and Control of Diabetes in the 
Basic Health Unit of Jatai municipality. Inclusion 
criteria of the diabetic group were the diagnosis of 
DM2; blood tests associated to the diabetes control 
performed in the last two years; glycated haemoglobin 
(HbA1c) > 6.5%. 
- Inclusion criteria of the diabetic group were the 
diagnosis of DM2, and > 30 years old; blood tests 
associated to the diabetes control performed in the last 
two years.
- The control group (n = 76) included T2D patients’ 
companions or other patients in treatment at the Basic 
Health Unit, who have declared not to have T2D; 
had the glycated haemoglobin (HbA1c) evaluated 
with results < 6.5% and have not used anthelmintic/
antiprotozoal drugs in the last year.
Fecal samples were immediately transported to the 
Laboratorio de Parasitologia, Universidade Federal de Jataí 
in Goias State, and processed within 12 h of collection by 
Lutz and Baermann modified methods for microscopic 
examination16. A second aliquot was immediately frozen at 
-20 °C for extracting genomic DNA. This subsample set was 
shipped to Laboratorio de Investigacao Medica (LIM/06), 
Hospital das Clinicas of the Faculdade de Medicina of the 
Universidade de Sao Paulo, for molecular analysis. 
DNA extraction and PCR amplification 
Genomic DNA was extracted directly from fecal 
samples using the QIAamp Stool Mini Kit (QIAGEN, 
Hilden, Germany), according to the manufacturer’s 
recommendations. DNA was eluted in a final volume of 
100 μL and stored at -20ºC in the freezer until the PCR 
(Polymerase Chain Reaction) analysis. DNA isolates 
were analysed for the presence of Blastocystis sp. through 
PCR performed with pan-Blastocystis primers RD5 
(5’-ATCTGGTTGATCCTGCCAGT-3’) and BhRDr 
(5’-GAGCTTTTAACTGCAACAA CG-3’) described 
by Scicluna et al.17, that amplify a DNA fragment of 
approximately 600 bp from the SSU rDNA gene. 
Four microliters of the DNA solution were added into 
the standard PCR mixture with a total reaction volume 
of 20 μL. GoTaq® DNA Polymerase (5 U/μL, Promega 
Corporation, Madison, WI, USA) was used in all the PCR 
reactions. Amplification cycles were composed of an initial 
denaturation step of 94 °C for 2 min, followed by 30 cycles of 
94 ºC for 1 min (denaturation), 61.8 ºC for 1 min (annealing) 
and 72 ºC for 1 min (extension), and a final extension of 72 
ºC for 2 min. In all PCR amplifications, a positive control 
(PCR mixture with Blastocystis sp. culture isolate) and a 
negative control (PCR mixture with non-template water) 
were included. Amplification products were analysed on 
2% agarose gel electrophoresis stained with Sybr Safe 
(Invitrogen™, Thermo Fisher Scientific Corporation, 
Waltham, USA) and visualized under UV light. 
Subtyping and phylogenetic analyses of Blastocystis 
sp. 
PCR products were purified using the Exo-SAP-IT™ 
PCR clean-up (USB Corporation, Cleveland, Ohio, USA) 
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and sequenced by the two-directional sequencing for 
increasing the sequencing accuracy using the BigDye 
Terminator v3.1 cycle sequencing kit and the same primers 
used in the PCR. Sequencing data were generated on an 
ABI 3500 automated DNA sequencer (Applied Biosystems, 
Thermo Fisher Scientific, Waltham, USA).
The quality of sequences was evaluated using the Phred-
Phrap software and the consensus sequence of each sample 
was assembled using the CAP3 software available at the 
Electropherogram quality analysis webpage18. Sequences 
were aligned and edited when necessary using CLUSTAL 
W and BioEdit v.7.0.8 software programs (Ibis Bioscience, 
Carlsbad, CA, USA). 
For subtypes identification the consensus sequence of 
each sample was analyzed using the Basic Local Alignment 
Search Tool (BLASTn)19. Sequences were also submitted 
to phylogenetic analysis together with published reference 
sequences from the GenBank database to confirm the 
subtype classification. Subtype identification and allele 
discrimination based on 18S rRNA gene of Blastocystis 
were performed using the Blastocystis database20.
Phylogenetic analysis was performed with the Mega 
software (Version 10) through the Molecular Evolutionary 
Genetics Analysis package, using the Maximum Likelihood 
method and Tamura 3-parameter model21. Genetic distances 
were calculated using Kimura’s two-parameter model. 
Bootstrap analysis with 1,000 replicates was performed to 
test the reliability of the tree with values ≥ 70 indicated on 
the branches. 
Data analysis
The agreement between microscopy and molecular 
analyses was measured using the Cohen’s kappa coefficient 
(κ) (GraphPad Prism®, Melbourne, Australia). The data 
were analyzed using the Fisher’s exact test to compare 
the frequency data generated by the study groups. Odds 
ratios (ORs) and their corresponding 95% confidence 
intervals (CIs) were used. A p value < 0.05 was considered 
statistically significant. 
RESULTS
Fecal samples were collected from a total of 
175 individuals. The diabetic group was composed of 38 
(38.4%) males and 61 (61.6%) females, ranging from 32 
to 87 years (62.8 ± 10.5 years), with a mean HbA1c of 
8.9% (ranging from 6.8 to 16.8%) The control group was 
composed of 33 (43.4%) males and 43 (56.6%) females, 
ranging from 21 to 89 years (56.6 ± 18.5 years). There was 
no statistically significant difference in the comparison of 
variables between the two groups. 
Overall, the microscopic examination revealed the 
presence of parasites in 31.3% (31/99) of the diabetic 
patients who harbored at least one intestinal parasite/
commensal species. The most predominant species were 
non-pathogenic amebae (42.42%, 42/99); followed by 
Blastocystis sp. (12.1%, 12/99), Entamoeba hystolytica 
complex (2.02%, 2/99), Giardia intestinalis (1.01%, 
1/99), and by helminths Strongyloides stercoralis and 
Hymenolepsis nana (1.01%, 1/99). In the control group, 
the microscopic examination showed that 25% (19/76) 
of fecal samples had at least one intestinal parasite/
commensal species. Among identified species, there were 
non-pathogenic amebae (36.84%, 28/76); followed by 
Blastocystis sp. (7.89%, 6/76), Entamoeba hystolytica 
complex (5.26%, 4/76), and by helminths S. stercoralis and 
Trichuris trichiura (1.32%, 1/76). 
PCR products of the expected size (around 600 bp) were 
observed in 44.4% (44/99) and in 34.2% (26/76) of the DNA 
samples from the diabetic and control groups, respectively, 
p > 0.05. Among the 70 PCR-positive samples, 57 (34 and 
23 from the diabetic and control groups, respectively) were 
confirmed to be positive to Blastocystis by the sequencing 
of the amplification product. A total of 13 samples were 
excluded due to poor sequence quality (n  =  7) and no 
similarity with Blastocystis in GenBank (n = 6). Additional 
analyses are being conducted to accurately determine their 
taxonomic identity.
Considering the results of the microscopic and molecular 
analyses, 36.0% (63/175) of the samples were positive 
for Blastocystis. Comparing the number of Blastocystis-
positive samples identified by microscopy and molecular 
analyses, a low concordance was observed [κ = 0.194 
(0.060–0.328)], p < 0.001. Six samples (three in each group) 
were Blastocystis sp.-positive by microscopy, nonetheless, 
they were negative by molecular analyses. Table 1 shows the 
distribution of diabetic and control participants according 
to age, gender and Blastocystis-positive results. 
The 57 successfully subtyped sequences showed a high 
similarity (98.78 to 100%) in comparison with Blastocystis 
sequences reported in GenBank (Supplementary Table S1). 
The nucleotide sequences obtained in this study have been 
deposited in the GenBank database under the accession 
numbers: MN585810-MN585817, MN585819, MN585821-
MN585822, MN585824, MN585826-MN585832, 
MN585834-MN585837, MN585839, MN585841-
MN585847, MN585849-MN585850, MN585852, 
MN585854-MN585864, MN585866-MN585867 and 
MN585870-MN585879. 
The nucleotide sequence analysis revealed the presence 
of six subtypes among the diabetic isolates: ST1 (13/34; 
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38.2%), ST2 (4/34; 11.8%), ST3 (12 /34; 35.3%), ST6 
(1/34; 2.9%), ST7 (1/34; 2.9%) and ST8 (3/34; 8.8%). 
Subsequently, we identified the alleles present in each 
subtype from isolates of the diabetic group: ST1 (allele 4), 
ST2 (alleles 9 and 12), ST3 (alleles 34, 36 and 37), ST6 
(allele 122), ST7 (allele 99) and ST8 (allele 21) (Table 2, 
Supplementary Table S1). In the control group, five subtypes 
were identified: ST1 (5/23; 21.8%), ST2 (5/23; 21.8%), ST3 
(10/23; 43.5%), ST6 (1/23; 4.4%) and ST8 (2/23; 8.7%). 
The following were identified in the ST1 (allele 4), ST2 
(alleles 11 and 15), ST3 (alleles 34 and 36), ST6 (allele 
134) and ST8 (allele 21) (Table 2, Supplementary Table S1). 
The higher occurrence of ST1 in diabetic isolates in relation 
to the control group (72.2 vs 27.8%; p = 0.01030) can be 
observed. There was no significant difference between the 
other subtypes. 
Based on the barcode sequence the similarity of the 
sequences within each subtype was calculated and showed a 
range from 99.987 to 100%. Considering the inter-subtypes 
ST1 and ST2 (99.974) shows highest similarity, while ST2 
and ST7 (99.849) shows lowest similarity. To establish a 
probable correlation between diabetic and intra-subtype 
variation, genetic similarity between sequences of diabetic 
and controls isolates among each subtype was calculated, 
and it showed the lowest similarity in ST2 (99.994%) versus 
the highest similarity in ST3 isolates (100%). 
A Phylogenetic tree was constructed, and it revealed 
that all six subtypes were clearly separated (Figure 1). 
Moreover, the tree indicated that sequences obtained from 
the Blastocystis isolates from the diabetic group were not 
separated from those from the control group. This suggests 
that there was no association between the presence of 
diabetes and Blastocystis sp.
DISCUSSION 
Blastocystis sp. has been one of the most prevalent 
anaerobic protists found in human fecal specimens22. 
However, it still remains surrounded by many uncertainties, 
especially regarding its pathogenic potential7. Patients with 
diabetes mellitus can present intestinal parasites infections 
with more serious complications5. In addition, the literature 
Table 1 - Association between the positivity to Blastocystis sp. and characteristics of the diabetic and the control group.
Diabetic group Control group P value OR (95% CI )
Characteristics
Gender*
♂ 15 (40.5%) 14 (46.1%) 0.8060 0.8866 (0.3382-2.323)
♀ 22 (59.5%) 12 (53.9%) 0.3938 1.452 (0.6226 -3.474)
Age*
< 65 years 14 (37.8%) 16 (61.5%) 0.3328 0.6539 (0.2745-1.544)
≥ 65 years 23 (62.2%) 10 (38.5%) 0.1278 2.154 (0.8054 -5.955)
Results
Microscopy 12 (12.1%) 6 (7.9%) 0.3779 1.605 (0.5774 -4.846)
PCR 34 (34.4%) 23 (30.3%) 0.5745 1.204 (0.6332 -2.309)
*considering the results of microscopy and the molecular analyses
Table 2 - Distribution of Blastocystis sp. subtypes and alleles in the diabetic and the control group.
Subtypes
Diabetic group Control group Total
Alleles n (%) Alleles n (%) Alleles n (%)
ST1 4 13/13 100 4 5/5 100 4 18/18 100
ST2
9 1/4 25 - - - 9 1/9 11.1
- - - 11 3/5 60 11 3/9 33.3
12 3/4 75 - - - 12 3/9 33.3
- - - 15 2/5 40 15 2/9 22.2
ST3
34 6/12 50 34 8/10 80 34 14/22 63.6
36 2/12 16.7 36 2/10 20 36 4/22 18.2
37 4/12 33.3 - - - 37 4/22 18.2
ST6
122 1/1 100 - - - 122 1/2 50
- - - 134 1/1 100 134 1/2 50
ST7 99 1/1 100 - - - 99 1/1 100
ST8 21 3/3 100 21 2/2 100 21 5/5 100
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Figure 1 - Phylogenetic analysis of Blastocystis SSU rDNA sequences (around 600bp) generated in the diabetic group (identified 
by filled black triangles) and the control group (identified by empty black triangles). Reference sequences from GenBank (identified 
by accession numbers and subtypes). The phylogenetic tree was constructed using the Maximum Likelihood method. Bootstrap 
values < 70% are not shown. The subtype prevalence in the 57 samples is shown on the right as a percentage.
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has been emphasized the high frequency of protozoan and 
helminths in patients with type 2 diabetes in relation to 
type 1 diabetes10. It is worth noting that, to our knowledge, 
there are no studies conducted in Brazil that explored the 
occurrence of Blastocystis sp. in patients with diabetes 
mellitus. 
Parasitological techniques by microscopy are used as 
the main diagnostic tool for Blastocystis in the majority of 
laboratories. In the present study, Blastocystis positivity by 
microscopic examination of 12.1% and 7.9% were observed 
in the diabetic and the control group, respectively. This 
positivity was lower in previous studies12,23 and higher in 
others11,13,14 carried out in the Midwest region of Brazil. 
In addition, Bafghi et al.5 demonstrated inferior results 
(2.4%) in diabetic patients’ from Iran. In our study, we 
used parasitological techniques employed in the routine 
of clinical laboratories that may have contributed to the 
low positivity. However, some authors have reported the 
importance of using stained smears and culture methods 
for the diagnosis of Blastocystis6,22, mainly to improve the 
visualization and distinction of Blastocystis forms6.
Poor quality sequences were not considered in the 
genetic analysis. These sequences may occur due to 
incomplete replication of the DNA strand during the cycle 
as a result of a PCR product combining sequences from 
the two sources (different organisms)24; or due to the 
extensive sequence similarity in some regions of the SSU 
rDNA25. Thus, the positivity of Blastocystis should always 
be confirmed by sequencing.
Molecular analysis (34.4% and 30.3% in the diabetic 
and the control groups, respectively) showed a higher 
positivity in relation to the microscopic examination. One 
possible explanation is that the non-use of high sensitivity 
parasitological techniques to detect this protist22. On the 
other hand, it is important to highlight the occurrence 
of some positive parasitological samples that were 
PCR-negative. Isolates that were not amplified by pan-
Blastocystis primers (barcode region) or the presence of 
PCR inhibitors in fecal samples can be considered to explain 
the non-amplification of Blastocystis DNA26. In addition, 
in Blastocystis research, molecular tools can have a crucial 
impact on the understanding of its epidemiology, genetic 
diversity and transmission27. Thus, our findings reinforce the 
usefulness of PCR, followed by sequencing, as a sensitive 
diagnostic method for the detection of this organism.
In the last years, a variety of studies have been developed 
to identify Blastocystis sp. subtypes that were circulating 
in the human population7,8. Through the molecular 
identification of the barcode region, six subtypes were 
identified: ST1, ST2, ST3, ST6, ST7 and ST8. Globally, 
subtypes ST1-ST4 have been identified as the most 
common in humans7,8. It is interesting to note that there 
was a predominance of ST1, followed by ST3 and ST8 in 
diabetics, whileST3 was observed followed by ST1 and ST2 
in the control group. In the Midwest region, only one study23 
evaluated the presence of Blastocystis subtypes reinforcing 
the greater occurrence of ST1, followed by ST2 and ST3. In 
other regions of Brazil, the situation is similar to the results 
of the control group with the highest occurrence of ST3, 
followed by ST1 and ST228-31.
The identification of ST6-ST8 subtypes can characterize 
a potential area for zoonotic transmission. Subtypes 6 
and 7 are usually found in birds, while ST8 is commonly 
found in non-human primates and it has also been reported 
in marsupials8. These subtypes are found sporadically in 
humans, with lower frequencies7,8. ST6 and ST8 were 
identified in other Brazilian isolates, recently reported by 
Melo et al.30 and Seguí et al.28, who analyzed clinical stool 
samples in Sao Paulo State and fecal samples of children 
in Parana State, respectively. Curiously, ST7 was detected 
only in the Brazilian studies carried out in the Southeast 
region31,32. In the present study, we observed relatively 
high occurrences of these subtypes, mainly ST8 (8.8% of 
diabetic and 8.7% of control isolates). Interestingly, in our 
results, there were no mixed infections among our isolates. 
Blastocystis 18S alleles retrieved for each ST showed 
particular alleles in patients with diabetes mellitus, such as 
alleles 9 and 12 (ST2), allele 37 (ST3) and allele 122 (ST6), 
whereas in the control group isolates, alleles 11 and 
15 (ST2) and allele 134 (ST6) were identified. The genetic 
diversity of alleles in this study was low when compared 
to studies already reported in Brazil28,31,32. Nonetheless, it 
should be noted that the allele 99 (ST7) was identified, and 
it had not yet been described in Brazil until now. Lastly, 
the presence of particular alleles associated with clinical 
implications needs to be further studied. In addition, 
different subtypes of Blastocystis appear to modulate the 
intestinal microbiota differently33, and nutritional status of 
the individual may be an important risk factor34.
Globally, the prevalence of Blastocystis infections in the 
two groups was similar in the present study, corroborating 
the results from a study carried out in Thailand35, that 
evaluated the presence of Blastocystis in diabetics and non-
diabetics. Nevertheless, other studies indicated that type 2 
diabetes in humans can be associated with compositional 
changes in the intestinal microbiota36, favouring the 
occurrence of Blastocystis in this group of patients.
The present study has some limitations that may have 
prevented us from reaching more robust conclusions, such 
as the accuracy of the parasitological diagnosis, as well 
as the lack of clinical and epidemiological data (location, 
previous contact with animals, presence or absence of 
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symptoms etc). Sociodemographic, hygienic and clinical 
aspects would have been very important, especially to 
understand the possible association between Blastocystis 
sp. Infections and patients with diabetes mellitus.
CONCLUSIONS 
In conclusion, the present study is the first report 
regarding Blastocystis sp. occurrence and subtype 
distribution. in patients with diabetes mellitus in Brazil. 
This protist was more identified in the T2D group than in 
the control group. Although we observed no association 
between Blastocystis infection and diabetes, the potential 
risk of Blastocystis infection should not be excluded. All 
things considered, our results update the distribution of the 
subtypes and alleles of Blastocystis sp. in Brazil. 
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Supplementary Table S1 - Subtyping of Blastocystis isolates from diabetics and control groups.
Isolates Genbank identification Identity (%)* 
Subtypes/Alleles








191 MN585811.1 99.011 4 - - - - -
200 MN585813.1 99.171 4 - - - - -
206 MN585814.1 99.181 4 - - - - -
267 MN585815.1 99.301 4 - - - - -
587 MN585822.1 99.011 4 - - - - -
874 MN585828.1 99.311 4 - - - - -
989 MN585832.1 99.481 4 - - - - -
1073 MN585835.1 99.311 4 - - - - -
1074 MN585836.1 98.782 4 - - - - -
1079 MN585837.1 99.501 4 - - - - -
1089 MN585842.1 99.311 4 - - - - -
1096 MN585844.1 99.661 4 - - - - -
1100 MN585847.1 99.661 4 - - - - -
89 MN585810.1 98.893 - 12 - - - -
1097 MN585845.1 99.303 - 12 - - - -
1098 MN585846.1 99.343 - 12 - - - -
28998 MN585852.1 99.303 - 9 - - - -
401 MN585816.1 99.834 - - 36 - - -
423 MN585817.1 99.834 - - 34 - - -
566 MN585819.1 99.834 - - 34 - - -
713 MN585824.1 99.674 - - 34 - - -
799 MN585826.1 1005 - - 34 - - -
838 MN585827.1 99.834 - - 34 - - -
919 MN585829.1 1004 - - 36 - - -
933 MN585830.1 1004 - - 34 - -
1057 MN585834.1 99.836 - - 37 - - -
1084 MN585839.1 99.835,6 - - 37 - - -
1087 MN585841.1 99.834,5,6 - - 37 - - -
1094 MN585843.1 99.836 - - 37 - - -
1104 MN585849.1 99.667 - - - 122 - -
952 MN585831.1 1008 - - - - 99 -
192 MN585812.1 99.649 - - - - - 21
586 MN585821.1 99.829 - - - - - 21








C9 MN585856.1 99.501 4 - - - - -
C14 MN585857.1 99.011 4 - - - - -
C29 MN585864.1 99.341 4 - - - - -
C65 MN585870.1 99.501 4 - - - - -
C38 MN585866.1 99.501 4 - - - - -
C7 MN585855.1 99.673 - 11 - - - -
C20 MN585861.1 99.663 - 11 - - - -
C22 MN585862.1 99.673 - 11 - - - -
C89 MN585877.1 99.003 - 15 - - - -
C117 MN585879.1 99.013 - 15 - - - -
C5 MN585854.1 99.834,5,6 - - 34 - - -
C16 MN585858.1 1004 - - 34 - - -
C17 MN585859.1 99.674 - - 34 - - -
C19 MN585860.1 1004 - - 34 - - -
C24 MN585863.1 1005,6 - - 36 - - -
C67 MN585871.1 1004 - - 34 - - -
C71 MN585872.1 1004 - - 34 - - -
C72 MN585873.1 99.834,5,6 - - 34 - - -
C73 MN585874.1 99.834,5,6 - - 34 - - -
C101 MN585878.1 99.674 - - 36 - - -
C86 MN585876.1 99.497 - - - 134 - -
C47 MN585867.1 99.829 - - - - - 21
C77 MN585875.1 99.829 - - - - - 21
*Identity (%) with the following reference sequences retrieved from GenBank: ST1 (U51151; human)1 and (MK719677; human)2; ST2 
(AB070987; human)3; ST3 (AB070988; human)4, (MG807915; human)5 and (MK719673)6; ST6 (AB107972; bird)7; ST7 (DQ232821; human)8 
and ST8 (DQ462720; non-human primate)9. 
